AstraZeneca PLC (AZN)vsPrecigen Inc (PGEN)
AZN
AstraZeneca PLC
$160.17
+0.33%
HEALTHCARE · Cap: $252.33B
PGEN
Precigen Inc
$6.85
+2.54%
HEALTHCARE · Cap: $2.46B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 71491% more annual revenue ($61.37B vs $85.72M). AZN leads profitability with a 17.0% profit margin vs -184.0%. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
PGEN
Hold40
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Intrinsic value data unavailable for PGEN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Strong operational efficiency at 41.2%
Revenue surging 6323.0% year-over-year
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
0.0% earnings growth
Weak financial health signals
Trading at 57.1x book value
ROE of -1145.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : PGEN
The strongest argument for PGEN centers on Operating Margin, Revenue Growth. Revenue growth of 6323.0% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : PGEN
The primary concerns for PGEN are EPS Growth, Piotroski F-Score, Price/Book. Debt-to-equity of 2.26 is elevated, increasing financial risk.
Key Dynamics to Monitor
AZN profiles as a mature stock while PGEN is a hypergrowth play — different risk/reward profiles.
PGEN carries more volatility with a beta of 1.02 — expect wider price swings.
PGEN is growing revenue faster at 6323.0% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 40/100), backed by strong 17.0% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Precigen Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Precigen, Inc. discovers and develops the next generation of cell and gene therapies in the United States. The company is headquartered in Germantown, Maryland.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?